Mind + Muscle

technical minds + legal muscle


dig deep

Glenmark Settles Litigation with Daiichi Sankyo, Genzyme over Welchol (Colesevelam Hydrochloride)

  • 07.08.11
  • Sterne, Kessler, Goldstein & Fox P.L.L.C.

Glenmark Pharmaceuticals successfully settled its litigation with Daiichi Sankyo and Genzyme Corporation regarding Glenmark's Abbreviated New Drug Application (ANDA) for Welchol® (Colesevelam Hydrochloride), a drug used in treatment of type-2 diabetes.  As a result of the settlement, Glenmark has received a license from Daiichi Sankyo and Genzyme that will permit Glenmark to launch its generic Colesevelam Hydrochloride products on April 02, 2015 or earlier under certain circumstances.

The Sterne Kessler litigation team that successfully represented Glenmark in this matter included H. Keeto Sabharwal, Daniel E. Yonan, and Jeremiah B. Frueauf.

Read the full press release at Business Standard.

Download the attached PDF to read the decision.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.